PMCCPMCCPMCC

Search tips
Search criteria 

Advanced


 
Formats
Article sections
Authors
Related links
Logo of bmcurolBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Urology
 
BMC Urol. 2008; 8: 20.
Published online 2008 December 23. doi:  10.1186/1471-2490-8-20
PMCID: PMC2630990
Copyright © 2008 Rosser; licensee BioMed Central Ltd.
Prostate Cancer – To screen, or not to screen, is that the question?
Charles J Rossercorresponding author1
1Department of Urology and Pharmacology and Therapeutics, University of Florida, Gainesville, Florida, USA
corresponding authorCorresponding author.
Charles J Rosser: charles.rosser/at/urology.ufl.edu
Received November 17, 2008; Accepted December 23, 2008.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Small right arrow pointing to: This article has been cited by other articles in PMC.
Abstract
There continues to be controversy regarding serum Prostate-Specific Antigen (PSA) and prostate cancer screening. We anxiously await the results of two large prospective randomized clinical trials (Prostate, Lung, Colon, and Ovary-PCLO screening trial in the US and European Randomized Study of Screening for Prostate Cancer-ERSPC in Europe) assessing the benefits of prostate cancer screening. However the true question to answer may be which cancer to treat and when should we treat it.
Articles from BMC Urology are provided here courtesy of
BioMed Central